Table 4 Administration setting (%) for biologic agents
From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
Agent | Hospital | Pharmacy | Dermatologist’s private office | Nurse at home | Alone at home | Health center/private clinic |
|---|---|---|---|---|---|---|
Adalimumab | 9 | 12 | 2 | 8 | 60 | 8 |
Etanercept | 11 | 12 | 4 | 9 | 58 | 7 |
Infliximab | 99 | 0 | 1 | 0 | 0 | 0 |
Ustekinumab | 68 | 3 | 2 | 16 | 12 | 0 |